A subset of flavaglines inhibits KRAS nanoclustering and activation
The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loa...
Saved in:
Main Authors: | Yurugi, Hajime, Zhuang, Yinyin, Siddiqui, Farid A., Liang, Hong, Rosigkeit, Sebastian, Zeng, Yongpeng, Abou-Hamdan, Hussein, Bockamp, Ernesto, Zhou, Yong, Abankwa, Daniel, Zhao, Wenting, Désaubry, Laurent, Rajalingam, Krishnaraj |
---|---|
其他作者: | School of Chemical and Biomedical Engineering |
格式: | Article |
語言: | English |
出版: |
2021
|
主題: | |
在線閱讀: | https://hdl.handle.net/10356/149025 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
相似書籍
-
CHARACTERIZTION OF LoxP-krasV12 TRANSGENIC ZEBRAFISH FOR INTESTINE SPECIFIC TUMORIGENESIS
由: ANEEKET JETLEY
出版: (2023) -
GENERATION AND ANALYSES OF krasV12 TRANSGENIC ZEBRAFISH TO STUDY INTESTINE TUMORIGENESIS
由: DIVYA RAGHURAM
出版: (2018) -
KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
由: Lam, KK, et al.
出版: (2024) -
RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
由: Omar, M.F.M., et al.
出版: (2014) -
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
由: Kim, H.R., et al.
出版: (2014)